Literature DB >> 12821614

More than just hype.

Salim Yusuf, Gilles Dagenais.   

Abstract

Mesh:

Substances:

Year:  2003        PMID: 12821614      PMCID: PMC161605     

Source DB:  PubMed          Journal:  CMAJ        ISSN: 0820-3946            Impact factor:   8.262


× No keyword cloud information.
  11 in total

1.  Ramipril use in Canada: HOPE or HYPE?

Authors:  Louise Pilote
Journal:  CMAJ       Date:  2003-03-04       Impact factor: 8.262

2.  Economic impact of ramipril on hospitalization of high-risk cardiovascular patients.

Authors:  Cathryn A Carroll; Michael M Coen; Robert W Piepho
Journal:  Ann Pharmacother       Date:  2003-03       Impact factor: 3.154

3.  Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients.

Authors:  S Yusuf; P Sleight; J Pogue; J Bosch; R Davies; G Dagenais
Journal:  N Engl J Med       Date:  2000-01-20       Impact factor: 91.245

4.  Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial.

Authors:  Jackson T Wright; George Bakris; Tom Greene; Larry Y Agodoa; Lawrence J Appel; Jeanne Charleston; DeAnna Cheek; Janice G Douglas-Baltimore; Jennifer Gassman; Richard Glassock; Lee Hebert; Kenneth Jamerson; Julia Lewis; Robert A Phillips; Robert D Toto; John P Middleton; Stephen G Rostand
Journal:  JAMA       Date:  2002-11-20       Impact factor: 56.272

5.  The cost-effectiveness of ramipril in the treatment of patients at high risk of cardiovascular events: a Swedish sub-study to the HOPE study.

Authors:  I Björholt; F L Andersson; T Kahan; J Ostergren
Journal:  J Intern Med       Date:  2002-06       Impact factor: 8.989

6.  The striking effect of the Heart Outcomes Prevention Evaluation (HOPE) on ramipril prescribing in Ontario.

Authors:  Karen Tu; Muhammad M Mamdani; Robert M Jacka; Natalie J Forde; Deanna M Rothwell; Jack V Tu
Journal:  CMAJ       Date:  2003-03-04       Impact factor: 8.262

7.  Cost implications of the use of ramipril in high-risk patients based on the Heart Outcomes Prevention Evaluation (HOPE) study.

Authors:  Andre Lamy; Salim Yusuf; Janice Pogue; Amiram Gafni
Journal:  Circulation       Date:  2003-02-25       Impact factor: 29.690

8.  Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators.

Authors: 
Journal:  Lancet       Date:  1993-10-02       Impact factor: 79.321

9.  Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Ramipril Efficacy in Nephropathy.

Authors:  P Ruggenenti; A Perna; G Gherardi; F Gaspari; R Benini; G Remuzzi
Journal:  Lancet       Date:  1998-10-17       Impact factor: 79.321

10.  Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials.

Authors:  R Garg; S Yusuf
Journal:  JAMA       Date:  1995-05-10       Impact factor: 56.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.